Puma Biotechnology Inc (PBYI) : The money flow analysis of Puma Biotechnology Inc (PBYI) indicates a $5.37 million of outflow was on downticks, whereas, the investors on Friday gobbled up stocks worth $6.29 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.17 and so was the total money flow at $0.92 million. The bulls lapped up $0 million worth of block trades on upticks. The money flow was $0 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Puma Biotechnology Inc (PBYI), pushing it down by -1.81% for the day. The stock slid $1.06 and traded at $57.65 during the day. Nonetheless, the stock is 0.03% over the previous weeks close.
The company Insiders own 22.7% of Puma Biotechnology Inc shares according to the proxy statements. Institutional Investors own 98.07% of Puma Biotechnology Inc shares.
In a related news, The Securities and Exchange Commission has divulged that Bryce Richard Paul, officer (SR VP, CLINICAL RESEARCH & DEV) of Puma Biotechnology, Inc., had unloaded 3,000 shares at an average price of $110.03 in a transaction dated on July 6, 2015. The total value of the transaction was worth $330,090.
Puma Biotechnology Inc (NYSE:PBYI): stock was range-bound between the intraday low of $57.2 and the intraday high of $59.379 after having opened at $58.98 on Fridays session. The stock finally closed in the red at $58.98, a loss of -2.10%. The stock remained in the red for the whole trading day. The total traded volume was 447,160 shares. The stock failed to cross $59.379 in Fridays trading. The stocks closing price on Thursday was $58.71.
Puma Biotechnology Inc (PBYI) has risen sharply, recording gains of 19.03% in the past 4 weeks. However, the stock has corrected -0.26% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 19.19% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.